Actuate Therapeutics, Inc. (NASDAQ:ACTU – Free Report) – Equities research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Actuate Therapeutics in a report issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $1.28 EPS.
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01.
View Our Latest Stock Report on ACTU
Actuate Therapeutics Trading Up 1.0%
Shares of NASDAQ ACTU opened at $1.06 on Thursday. Actuate Therapeutics has a 12 month low of $0.90 and a 12 month high of $9.22. The stock has a 50 day moving average of $1.44 and a 200-day moving average of $2.38. The company has a market capitalization of $25.45 million, a P/E ratio of -1.22 and a beta of 0.78.
Hedge Funds Weigh In On Actuate Therapeutics
Large investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in Actuate Therapeutics in the 2nd quarter valued at $28,000. ABS Direct Equity Fund LLC bought a new position in Actuate Therapeutics during the 4th quarter worth $40,000. Deutsche Bank AG increased its position in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after buying an additional 8,051 shares during the period. Barclays PLC lifted its holdings in shares of Actuate Therapeutics by 68.6% during the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after buying an additional 6,081 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Actuate Therapeutics by 61,068.0% during the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after buying an additional 15,267 shares in the last quarter.
Key Headlines Impacting Actuate Therapeutics
Here are the key news stories impacting Actuate Therapeutics this week:
- Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods. The firm improved its forecasts for Q3 and Q4 2026 EPS to $(0.15), compared with previous estimates of $(0.21) and $(0.23), respectively. It also raised estimates for Q1–Q4 2027 to losses of $(0.13), $(0.12), $(0.13), and $(0.13) per share. HC Wainwright Reiterates Buy Rating for Actuate Therapeutics
- Positive Sentiment: The full-year outlook also improved materially. HC Wainwright raised its FY2026 EPS forecast to $(0.61) from $(0.84), FY2027 to $(0.51) from $(0.71), and FY2028 to $(0.50) from $(0.75). The firm now expects Actuate to become profitable in FY2029, forecasting $0.15 per share versus its prior estimate of a $(0.07) loss, and increased its FY2030 forecast to $1.28 from $1.24.
- Positive Sentiment: HC Wainwright maintained its Buy rating. The repeated endorsement provides a favorable signal, particularly because the firm’s revised estimates imply faster improvement in profitability than previously expected. HC Wainwright Reiterates Buy Rating on Actuate Therapeutics
- Neutral Sentiment: The revisions are analyst projections rather than new operating results. Actuate remains unprofitable, with a consensus forecast of $(0.86) EPS for the current fiscal year, so the investment case continues to depend on execution and eventual clinical or commercial progress.
Actuate Therapeutics Company Profile
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
Featured Articles
- Five stocks we like better than Actuate Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
